JOINN (06127) surged more than 11% in Hong Kong trading, with shares last up 11.42% at HK$27.32, on turnover of HK$334 million.

The company recently released its first-half 2026 earnings forecast. According to China Post Securities, JOINN expects to report revenue of approximately RMB 669 million to RMB 739 million for the first half of 2026, representing a 0% to 10.5% year-on-year increase. Net profit attributable to shareholders is projected to be between RMB 600 million and RMB 900 million, a surge of 884.9% to 1,377.4% year-on-year, while core net profit is forecast at RMB 561 million to RMB 842 million, up 2,334.2% to 3,551.3% year-on-year.

China Post Securities noted that the positive fair value change in biological assets is the key driver behind JOINN's explosive earnings performance for the period. In the first half of 2026, the net profit contributed by the fair value change of biological assets is estimated at RMB 703 million to RMB 777 million, a significant increase from the RMB 88 million recorded in the same period of 2025. As a CRO company with its own breeding base for non-human primate experimental models, its population resource advantage not only secures the supply chain for its own non-clinical evaluation business but also directly translates into earnings flexibility through fair value revaluation.